Lipomics Technologies, a privately held company that specialises in lipid metabolite analysis and interpretation, has moved its operations to a new, larger facility
Lipomics first began operations in June 2000 in West Sacramento's Technology Development Center, a business incubator for technology and life science companies established by the late Charlie Soderquist and his business partners.
The new facility, with almost five times more laboratory space, will allow Lipomics to expand its technical platform to study a broader array of lipid metabolites, including low-abundance lipids that are extremely difficult to detect and measure. Currently Lipomics measures approximately 400 distinct lipid metabolites.
Additionally, Lipomics plans to roll out new diagnostic tools based on recent discoveries of novel biomarkers for metabolic dysregulation.
With lipids playing a central role in many of the industrialized world's leading disorders, Lipomics expects to be generating a steady flow of new diagnostic capabilities over the next several years.
These tools will initially be used in clinical trial and research settings.
Future applications in clinical practice promise more comprehensive and precise diagnostics of patient health compared to current diagnostic tools.
